Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990085 | 1.00 | GRM5 (0.58) | GRM5MTNR1AMTNR1BNPC1RAB9A | |
| SCHEMBL3627130 | 0.92 | GRM5 (0.58) | GRM5NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL990697 | 0.87 | GRM5 (0.53) | GRM5NPC1RAB9ASMN1; SMN2CYP1A2 | |
| SCHEMBL990047 | 0.87 | GRM5 (0.53) | GRM5SMN1; SMN2CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL990750 | 0.86 | GRM5 (0.56) | GRM5 | |
| SCHEMBL990045 | 0.85 | GRM5 (0.54) | GRM5CYP2C19 | |
| SCHEMBL990721 | 0.80 | GRM5 (0.56) | GRM5 | |
| SCHEMBL990246 | 0.79 | GRM5 (0.58) | GRM5 | |
| SCHEMBL14119620 | 0.78 | GRM5 (0.54) | GRM5 | |
| SCHEMBL5744089 | 0.78 | GRM5 (0.52) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009047303-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |